Get the Stockscreener App
49.93
2.00%
-1.02
After Hours:
49.93
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum Pharmaceuticals' SWOT analysis: FDA approvals boost rare disease stock - Investing.com
Deal pays off for drugmaker with approval for rare cholesterol-related disease treatment - The Business Journals
Mirum Pharmaceuticals Says US FDA Approves Cerebrotendinous Xanthomatosis' Treatment Drug - Marketscreener.com
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) - The Bakersfield Californian
Medical Milestone: First Treatment for CTX Patients Shows 20x Better Results Than Placebo - StockTitan
JMP maintains $74 target on Mirum Pharmaceuticals stock - Investing.com India
Mirum’s Ctexli wins FDA nod in cerebrotendinous xanthomatosis - BioWorld Online
US FDA approves Mirum Pharma's genetic disorder drug - Reuters
Mirum Pharmaceuticals' Lipid Storage Disease Treatment Gets FDA Approval -February 21, 2025 at 01:48 pm EST - Marketscreener.com
US FDA approves Mirum Pharma’s genetic disorder drug - KFGO
FDA Approves Mirum Pharmaceuticals Treatment for Lipid-Storage Disease -February 21, 2025 at 01:20 pm EST - Marketscreener.com
FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol - Benzinga
Mirum gains FDA approval of chenodiol for rare lipid storage disease - Seeking Alpha
FDA Approves Mirum Pharmaceuticals Treatment for Lipid-Storage Disease - MarketWatch
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 11:54 am EST - Marketscreener.com
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 - BioSpace
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 20 - WICZ
Mirum Pharma's Critical Q4 Earnings Call: Will 2024 Results Signal Growth Momentum? - StockTitan
High Growth Tech Stocks in United States to Watch - Simply Wall St
Mirum Pharmaceuticals stock soars to all-time high of $53.52 - Investing.com India
Mirum Pharmaceuticals stock soars to all-time high of $53.52 By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals (MIRM) is on the Move, Here's Why the Trend Could be Sustainable - MSN
How to Take Advantage of moves in (MIRM) - news.stocktradersdaily.com
Mirum Pharmaceuticals stock soars to all-time high of $48.94 - MSN
Alagille Syndrome Market Expected to rise, 2034 | Mirum Pharmaceuticals, Albireo, expected to drive market - Barchart
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharma (MIRM) Unveils Strategic Talent Package: 74K Shares in Equity Grants - StockTitan
SG Americas Securities LLC Sells 13,575 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 1,064 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Hits New 52-Week HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $126,673.94 in Stock - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 9,102 Shares - MarketBeat
(MIRM) Technical Pivots with Risk Controls - Stock Traders Daily
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Golden State Equity Partners Has $801,000 Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Genomenon and Mirum Pharmaceuticals Join Forces to Enhance CTX Disease Awareness and Diagnosis - PR Web
Alagille Syndrome Market is set for steady growth, with a robust - openPR
Mirum Pharmaceuticals president sells $126,680 in stock - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) shareholder returns have been solid, earning 192% in 5 years - Simply Wall St
Major Insider Stock Sales at Mirum Pharmaceuticals! - TipRanks
Mirum Pharmaceuticals president sells $126,680 in stock By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year HighShould You Buy? - MarketBeat
Mirum Pharmaceuticals stock soars to all-time high of $49.59 - MSN
First Week of MIRM March 21st Options Trading - Nasdaq
Mirum Pharmaceuticals stock soars to all-time high of $49.59 By Investing.com - Investing.com UK
Recent Price Trend in Mirum Pharmaceuticals (MIRM) is Your Friend, Here's Why - Yahoo Finance
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):